

# Isabelle Bence-Bruckler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2618549/publications.pdf>

Version: 2024-02-01

35  
papers

998  
citations

932766

10  
h-index

610482

24  
g-index

35  
all docs

35  
docs citations

35  
times ranked

1864  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib versus tamsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2016, 387, 770-778.	6.3	389
2	Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. <i>Lancet, The</i> , 2016, 388, 576-585.	6.3	296
3	Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. <i>Blood</i> , 2019, 133, 919-926.	0.6	89
4	Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation. <i>JAMA Neurology</i> , 2016, 73, 652.	4.5	71
5	Autologous Stem Cell Transplantation for Stiff Person Syndrome. <i>JAMA Neurology</i> , 2014, 71, 1296.	4.5	29
6	Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1197-1205.	2.0	17
7	Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial. <i>Blood</i> , 2018, 132, 787-787.	0.6	17
8	Autologous Stem Cell Transplant for Myasthenia Gravis: A Single-Centre Experience. <i>Blood</i> , 2014, 124, 3996-3996.	0.6	16
9	Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus tamsirolimus. <i>Leukemia and Lymphoma</i> , 2017, 58, 2824-2832.	0.6	15
10	Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial. <i>Blood</i> , 2016, 128, 1922-1922.	0.6	11
11	A Phase 2, Double-Blind, Placebo-Controlled Trial of Rituximab + Galiximab Vs Rituximab + Placebo In Advanced Follicular Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2010, 116, 428-428.	0.6	9
12	Whole brain radiotherapy improves survival outcomes in primary CNS lymphoma patients ineligible for systemic therapy. <i>Supportive Care in Cancer</i> , 2020, 28, 5363-5369.	1.0	8
13	Autologous Hematopoietic Stem Cell Transplantation for Liver Transplant Recipients With Recurrent Primary Sclerosing Cholangitis: A Pilot Study. <i>Transplantation</i> , 2022, 106, 562-574.	0.5	7
14	Disseminated histoplasmosis associated with acquired hemophagocytic lymphohistiocytosis. <i>Clinical Case Reports (discontinued)</i> , 2015, 3, 195-196.	0.2	5
15	Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study. <i>Blood</i> , 2019, 134, 3236-3236.	0.6	3
16	Ibrutinib Vs Tamsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2015, 126, 469-469.	0.6	3
17	Outcomes of both abbreviated hyperâ€CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10â€year singleâ€centre experience with literature review. <i>Cancer Medicine</i> , 2015, 4, 1817-1827.	1.3	2
18	Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study. <i>Blood</i> , 2020, 136, 16-16.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Rituximab Purging and Maintenance Improves Progression Free Survival but Not Overall Survival In Patients with Relapsed or Resistant Follicular Lymphoma Prior Receiving An Autologous Transplant. Blood, 2010, 116, 3567-3567.	0.6	2
20	Outcomes in Relapsed/Refractory Burkitt Lymphoma: A Multi-Centre Canadian Experience. Blood, 2021, 138, 2525-2525.	0.6	2
21	A Canadian Perspective on the First-Line Treatment of Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 303-313.	0.2	1
22	Low-Dose Anti-Thymocyte Globulin for Graft-Versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2016, 128, 5782-5782.	0.6	1
23	BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission. Blood, 2019, 134, 2933-2933.	0.6	1
24	The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up. Blood, 2019, 134, 1644-1644.	0.6	1
25	BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure. Blood, 2020, 136, 40-41.	0.6	1
26	The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia. Leukemia Research, 2020, 88, 106285.	0.4	0
27	Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH). Blood, 2010, 116, 1390-1390.	0.6	0
28	Interim Restaging PET/CT-Guided High Dose Sequential Induction Therapy with Autologous Stem Cell Transplantation (ASCT) Does Not Improve Outcome for Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL). ClinicalTrials.Gov Identifier: NCT00530179. Blood, 2011, 118, 500-500.	0.6	0
29	A Canadian Expanded Access Trial of Oral Nilotinib in Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase. Blood, 2011, 118, 4437-4437.	0.6	0
30	Retrospective Analysis of Allogeneic Transplant Outcomes in Chronic Myeloid Leukemia Patients with Tyrosine Kinase Inhibitors Failure. Blood, 2014, 124, 4554-4554.	0.6	0
31	Combined Modality Therapy in the Upfront Treatment of Patients with Primary Central Nervous System Lymphoma: A Systematic Review. Blood, 2015, 126, 5606-5606.	0.6	0
32	Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Temsirolimus. Blood, 2015, 126, 1542-1542.	0.6	0
33	Failure to Achieve Early Molecular Milestone within 3 Months Is Associated with Higher Risk of Relapse and Worse Survival after Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myeloid Leukemia Patients, Especially after Tyrosine Kinase Inhibitor Failure. Blood, 2016, 128, 1907-1907.	0.6	0
34	Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt. Blood, 2019, 134, 1653-1653.	0.6	0
35	Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial. Blood, 2020, 136, 54-55.	0.6	0